Joint Care Conversation Guide for Mild to Moderate Hemophilia A
After participating you can claim your CME credit here: https://forms.gle/dDAh7XCHoJTSXinPA
Accreditation: 0.25 AMA PRA Category 1 Credits™
Learning objectives
**
- Initiate timely prophylaxis in patients with mild to moderate hemophilia A to prevent joint deterioration:
- Identify patients with mild or moderate hemophilia A who may benefit from early initiation of prophylaxis.
- Explain the clinical evidence supporting early FVIII prophylaxis to reduce long-term joint complications.
- Implement strategies to overcome delayed treatment initiation in real-world care settings.
- Personalize hemophilia A treatment based on bleeding phenotype, activity level, and lifestyle:
- Assess individual patient risk factors, including activity level and bleeding history, to guide treatment personalization.
- Apply pharmacokinetic concepts and available tools to tailor prophylaxis regimens.
- Adapt treatment plans in response to changes in patient lifestyle, preferences, or clinical outcomes.
- Implement practical approaches for monitoring joint health in patients with non-severe hemophilia A:
- Recognize the importance of routine joint surveillance, even in the absence of overt bleeding symptoms.
- Utilize physical exams, patient-reported outcomes, and imaging to detect early signs of joint damage.
- Integrate joint health monitoring into multidisciplinary care plans to support early intervention and joint preservation.
This program is supported by an independent education grant from Bayer. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr Guy Young has disclosed financial relationships within the past 24 months with the following ineligible companies: Genetech/Roche, Sanofi, CSL Behring, Pfizer, and Hema Biologics. These relationships include consulting/speaker roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Young does not intend to discuss non-FDA uses of drug products and/or device.
Susan Knight PT, has disclosed financial relationships within the past 24 months with the following ineligible companies: Sanofi. These relationships include advisory board roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Susan Knight does not intend to discuss non-FDA uses of drug products and/or device.
AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE will designate this live activity for a maximum of 0.25 AMA PRA Category 1 Credits™.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
This program is supported by an independent education grant from Bayer. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.
Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.
Dr Guy Young has disclosed financial relationships within the past 24 months with the following ineligible companies: Genetech/Roche, Sanofi, CSL Behring, Pfizer, and Hema Biologics. These relationships include consulting/speaker roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Young does not intend to discuss non-FDA uses of drug products and/or device.
Susan Knight PT, has disclosed financial relationships within the past 24 months with the following ineligible companies: Sanofi. These relationships include advisory board roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Susan Knight does not intend to discuss non-FDA uses of drug products and/or device.
AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.
Mitigation of Relevant Financial Relationships AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE will designate this live activity for a maximum of 0.25 AMA PRA Category 1 Credits™.
Other Professionals All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.